106 related articles for article (PubMed ID: 19426700)
1. Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.
Chu C; Abbara C; Noël-Hudson MS; Thomas-Bourgneuf L; Gonin P; Farinotti R; Bonhomme-Faivre L
Biochem Pharmacol; 2009 May; 77(10):1629-34. PubMed ID: 19426700
[TBL] [Abstract][Full Text] [Related]
2. Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein.
Bonhomme-Faivre L; Benyamina A; Reynaud M; Farinotti R; Abbara C
Addict Biol; 2008 Sep; 13(3-4):295-300. PubMed ID: 18331373
[TBL] [Abstract][Full Text] [Related]
3. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice.
Manford F; Riffo-Vasquez Y; Spina D; Page CP; Hutt AJ; Moore V; Johansson F; Forbes B
J Pharm Pharmacol; 2008 Oct; 60(10):1305-10. PubMed ID: 18812023
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
Lagas JS; Vlaming ML; van Tellingen O; Wagenaar E; Jansen RS; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6125-32. PubMed ID: 17062689
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation.
Chu C; Noël-Hudson MS; Boige V; Goéré D; Marion S; Polrot M; Bigot L; Gonin P; Farinotti R; Bonhomme-Faivre L
Fundam Clin Pharmacol; 2013 Aug; 27(4):434-42. PubMed ID: 22458846
[TBL] [Abstract][Full Text] [Related]
6. Effect of interleukin-2 pretreatment on paclitaxel absorption and tissue disposition after oral and intravenous administration in mice.
Hosten B; Abbara C; Petit B; Dauvin A; Bourasset F; Farinotti R; Gonin P; Bonhomme-Faivre L
Drug Metab Dispos; 2008 Aug; 36(8):1729-35. PubMed ID: 18508881
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein (Abcb1) is involved in absorptive drug transport in skin.
Ito K; Nguyen HT; Kato Y; Wakayama T; Kubo Y; Iseki S; Tsuji A
J Control Release; 2008 Nov; 131(3):198-204. PubMed ID: 18725258
[TBL] [Abstract][Full Text] [Related]
8. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
Press RR; Buckle T; Beijnen JH; van Tellingen O
Cancer Chemother Pharmacol; 2006 Jun; 57(6):819-25. PubMed ID: 16163538
[TBL] [Abstract][Full Text] [Related]
9. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
Gnoth MJ; Sandmann S; Engel K; Radtke M
Drug Metab Dispos; 2010 Aug; 38(8):1341-6. PubMed ID: 20413726
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents.
O'Reilly T; McSheehy PM; Kawai R; Kretz O; McMahon L; Brueggen J; Bruelisauer A; Gschwind HP; Allegrini PR; Lane HA
Cancer Chemother Pharmacol; 2010 Mar; 65(4):625-39. PubMed ID: 19784839
[TBL] [Abstract][Full Text] [Related]
11. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein.
Kwei GY; Alvaro RF; Chen Q; Jenkins HJ; Hop CE; Keohane CA; Ly VT; Strauss JR; Wang RW; Wang Z; Pippert TR; Umbenhauer DR
Drug Metab Dispos; 1999 May; 27(5):581-7. PubMed ID: 10220486
[TBL] [Abstract][Full Text] [Related]
12. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted.
Smit JW; Schinkel AH; Weert B; Meijer DK
Br J Pharmacol; 1998 May; 124(2):416-24. PubMed ID: 9641561
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.
Kalvass JC; Olson ER; Pollack GM
Drug Metab Dispos; 2007 Mar; 35(3):455-9. PubMed ID: 17178769
[TBL] [Abstract][Full Text] [Related]
14. Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier.
Milane A; Fernandez C; Vautier S; Bensimon G; Meininger V; Farinotti R
J Neurochem; 2007 Oct; 103(1):164-73. PubMed ID: 17635670
[TBL] [Abstract][Full Text] [Related]
15. Effect of interferon-gamma on the pharmacokinetics of digoxin, a P-glycoprotein substrate, intravenously injected into the mouse.
Kawaguchi H; Matsui Y; Watanabe Y; Takakura Y
J Pharmacol Exp Ther; 2004 Jan; 308(1):91-6. PubMed ID: 14569074
[TBL] [Abstract][Full Text] [Related]
16. In situ intestinal perfusion in knockout mice demonstrates inhibition of intestinal p-glycoprotein by ritonavir causing increased darunavir absorption.
Holmstock N; Mols R; Annaert P; Augustijns P
Drug Metab Dispos; 2010 Sep; 38(9):1407-10. PubMed ID: 20551242
[TBL] [Abstract][Full Text] [Related]
17. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII).
Khariwala SS; Kjaergaard J; Lorenz R; Van Lente F; Shu S; Strome M
Laryngoscope; 2006 May; 116(5):814-20. PubMed ID: 16652094
[TBL] [Abstract][Full Text] [Related]
18. Blood concentrations of everolimus are markedly increased by ketoconazole.
Kovarik JM; Beyer D; Bizot MN; Jiang Q; Shenouda M; Schmouder RL
J Clin Pharmacol; 2005 May; 45(5):514-8. PubMed ID: 15831774
[TBL] [Abstract][Full Text] [Related]
19. Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys.
Tsukimoto M; Ohashi R; Torimoto N; Togo Y; Suzuki T; Maeda T; Kagawa Y
Biopharm Drug Dispos; 2015 Jan; 36(1):15-33. PubMed ID: 25264342
[TBL] [Abstract][Full Text] [Related]
20. Effect of itraconazole on the pharmacokinetics of everolimus administered by different routes in rats.
Yokomasu A; Yano I; Sato E; Masuda S; Katsura T; Inui K
Biopharm Drug Dispos; 2009 Dec; 30(9):517-23. PubMed ID: 19790241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
